Summary of Clinical Use

MOXR0916 is in early stage clinical trial in patients with solid tumours, as a monotherapy and in combination with the approved anti-PDL1 antibody atezolizumab. Click here to link to ClinicalTrials.gov's list of MOXR0916 trials.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03029832	A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy	Phase 2 Interventional	Genentech, Inc.	A note on this clonical trial record indicates that Genentech have made the decision to discontinue clinical development of MOXR0916 for business reasons.